Dow Jones 13676.32 +8.21 7:59 pm PDT, June 4, 2007 NASDAQ 2618.29 +4.37 For info, visit access.smallcapnetwork.com S & P 500 1539.18 +2.84 Change your subscription status here Russell 2000 855.09 +1.68 VOLUME 07 : ISSUE 55 BOCX: Tiny Cancer Test Has Huge Potential  Sometimes it pays to remember details. Those little things a company just mentions here and there can frequently come back to mean so much more later....and potentially reward those investors who kept track of them.  Take today's news from BioCurex Inc. (OTCBB: BOCX) for instance. The company gave us an update on a cancer-detection test they've been working on.....which seems to be quite effective. And this is no ordinary cancer test - at least not in my view. This is a rapid test, meaning it's a basic diagnostic tool that can be used in just one office visit. There's nothing else like it on the market, which is why I think it means extraordinary potential for BOCX owners.    Keep Coming Back To The Well  I'm going to guess we've all seen 'news' come and go. A lot of it means very little....a one-shot with no follow up, nor results. Some news, though, keeps coming back.  What's that got to do with BioCurex? This isn't the first time we've heard from BioCurex about this test. When a company bothers to keep coming back to a story, I generally think there's something substantial to it. Check out how far the test has come in just a few months:  February 13th: BioCurex started the development of a "point-of-care" cancer test which would be available for use at the doctor's office rather than in a laboratory setting.  May 2nd: The company re-announced its initiative to develop point-of-care tests, and said they'd be reporting results as they become available in a near future (like today).  Where some companies just release the same news over and over again, BioCurex actually has a real progress update. What a refreshing concept!  Simultaneously, I feel it's worth noting that press releases aren't free, and the R&D behind the test is certainly not free either. More than that, the test isn't even driving revenue yet. However, the company keeps developing the test, and continues to come back to the story and let the market know what's up, despite the price. Why do you think that is? My answer is also the reason I think an investor could justify becoming a BOCX owner. Like I've mentioned a handful of times recently, sometimes the right answer is indeed the obvious one.....I think the company really believes they have something here. In this case, I think BioCurex is providing regular updates just because they anticipate their rapid test being able to bear fruit eventually, and they just want give fair warning to the market.    What's The Big Deal?  The test utilizes BioCurex's impressive RECAF technology.....an accurate cancer detection marker that actually had its origins in a different format. The previous test required lab work to process, and therefore, took time - perhaps days. That can be excruciating for somebody worried about having cancer or not, not to mention costly for the patient or insurance company. The 'rapid test' - on the other hand - can be performed in a matter of minutes. And, since neither laboratory equipment nor a lot of manpower are needed, the cost is minimal.  Now, this isn't to say the rapid test is supposed to be everything its laboratory version is. This is designed to be a screener, not unlike a pregnancy test (which by the way is also not necessarily deemed to be a 'final determinant'). The aim is to devise an easy and quick way to decide if the higher-end lab test is even merited. But, if it filters out the majority of the people who either should or should not proceed to the lab test, it's still a very powerful (and money-saving) tool.  Does the test work? You know, I'm not a doctor, and the company even acknowledges there's a lot more R&D work to be done. But, take a look at the nearby image. The top, cancerous samples all look clearly different than the bottom, non-cancerous samples - at least to my amateur eyes. So, I personally have to believe the test is worth further trials, even if just for the sake of good science. The company appears to think so too.  Here's the nice part for investors....there's really no other in-office cancer screener out there. If this thing ends up being as effective as it seems to be and gets to the market, BioCurex could end up being the lone player in what we estimate is a multi-million dollar arena. Not too shabby.    Time-In, and Tim-ing  We've been following BioCurex for a long time - since 2003, to be exact. Some of you may remember our coverage that far back. If you do, then you may also remember BioCurex does a good job of actually making forward progress. They moved from being a pink sheet stock to the bulletin board. In recent testing, the RECAF cancer marker has shown to be a superior indicator of prostate, gastric, and breast cancer. Then they converted their laboratory version of the RECAF test from a radiological format to a more common colorimetric format. And today, they let us know the rapid version of the cancer test has early merit.  What's next? More than a few times the company has mentioned the possibility of not only using RECAF to mark potential cancer, but also as a way to actually deliver drugs to cancerous cells (but without affecting non-cancerous cells). If previous follow-through on plans is any indication of future intent, then we won't be surprised to start hearing news about that science as well. Is the stock likely to be an overnight sensation? Well, in all fairness, I've seen BOCX be catapulted instantaneously. However, my personal attraction to BioCurex is the long-term potential it has.....which is still enormous as far I'm concerned.  That said, I'd be kidding myself if I said I didn't look at short-term charts to time my long-term entries. Notice how the accumulation-distribution line has curled upward over the last few weeks. There are more buyers than sellers right now, which bodes well for the stock in the foreseeable future. If you also like getting into good investments at low levels, I believe the base around 53 cents may mark a nice, low-risk entry level for BioCurex shares.    BioCurex Reports Initial RECAF Cancer 'Rapid Test' Results  RICHMOND, British Columbia, June 4, 2007 -- BioCurex Inc. (OTCBB: BOCX) today announced that it is making progress on its initiative to develop point-of-care tests (also called 'Rapid Tests').  The company is pleased to report that preliminary results show it is possible to make such RECAF-based rapid tests for cancer detection.  The device used in the research is similar to the pregnancy tests that are commonly available for home use. Further details, as well as pictures of results are available at: http://biocurex.com/CUREXHTML/news/rapidtests.html Given the small number of samples tested, it is impossible to tell, at this time, whether or not it might be necessary to use a small portable instrument similar to the ones used to monitor blood sugar to read the intensity of the color of the band.  These experiments are very preliminary, and therefore no statistical conclusions can be drawn from this small number of samples. Furthermore, a significant amount of work needs to be done to perfect the test. Yet, the initial results strongly suggest that such a rapid test for cancer in general is feasible. This RECAF test format is intended to be used by physicians as a first approximation to the diagnosis of cancer and it will require confirmation by the more accurate, quantitative RECAF test performed by a clinical laboratory.  The company estimates the potential market for this test to be substantial. "We are very pleased with the preliminary results of our intensive R & D efforts and view this potential product as an important addition to our growing line of cancer detection technologies,'' stated Ricardo Moro, President and CEO. "The successful development of a rapid test for detecting cancer will position BioCurex as an industry innovator in this billion dollar market.''  About BioCurex:  BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.  BioCurex has signed a licensing agreement with Abbott Laboratories for BioCurex's RECAF(tm) Cancer technology as outlined in a joint press release dated March 29, 2005. The release noted that the cancer marker RECAF(tm) has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.  To read more about the Company, please visit the News section in our web site (http://www.biocurex.com).  Note:  The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.  Contact:  BioCurex, Inc.  Terry Johnston  (866) 884-8669  +1 604-267-3041   We Value Your Feedback   Got comments, questions or suggestions? Send 'em on over: Email the Editor If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 4653 Carmel Mtn Rd Suite 308 #402 San Diego, CA 92130 Phinder: New Name, Same Game Note that Phinder Technologies (OTCBB: PHDT) is slated to undergo a little cosmetic surgery - the company is changing their name to Zupintra Corporation Inc. in the near future. If the new name rings a bell, it's because 'Zupintra' is part of the name of the venture they're working on in South and Latin America....Zupintra-Panama.  Not a big deal, though I do like the convenience factor of having a corporate name match the name customers are familiar with.....it just eliminates any confusion. However, aside from the ticker and name change, nothing else is changing - Zupintra is still a high-octane company we think is on the verge of explosive growth.  For more on the name change, click here. However, there's not a whole lot to add other than what we just said. The company says they'll let us know more when the time comes.    Titan Ends Quarter With A Bang Sometimes the writing is on the wall....and I think this may be one of those times. On Friday, Titan Global (OTCBB: TTGL) let us know how well their PCB (printed circuit board) division was doing. Let's just say it was awesome. The thing is, I don't even think the press release really explained just how awesome it was. So, I will.  The PCB arm is actually the combination of their homeland security division, and electronics division. You may know the group better as PCB East and PCB West. Their total contribution pales in comparison to the kind of results their telecom business creates, but considering current TTGL owners are soon going to see the electronics division spun-off, you may be interested in understanding exactly what you're going to be receiving.  Check this out - in May, both the homeland security unit as well as the electronics unit drove record revenues....$2.6 million and $2.2 million, respectively. Any time a record is broken, I'm impressed. Yet, I think this may have been more impressive than it even seems.  Just for perspective, in all of last quarter, the PCB divisions pulled in $5.1 million. In just this past month, they pulled in $4.8 million. Can you say growth? It's just a something I wanted everyone to really understand, in case they were planning on shedding the spin-off as soon as it was completed. While the telecom side of the business creates the bulk of bucks, the electronics side may be the fastest-growing.  Still no word on the spin-off's completion date, but I suspect it will be 'soon'.  For more on last month's electronics revenues, click here.  Subscribe Information is power and timely information is profitable. Become informed and profit from Small Cap Network Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the Small Cap Network Email Newsletter on a regular basis. To ensure newsletter delivery, you can add any additional email addresses you may have to the Small Cap Network Member List. Receiving the Small Cap Network Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the Small Cap Network recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery. Subscribe Here Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the Small Cap Network Newsletter, simply follow the instructions located at the bottom of every Small Cap Network Newsletter Edition. Unsubscribe Here D I S C L A I M E R: The Small Cap Network, its website and email newsletter (hereafter, cumulatively referred to as "SCN") , is an independent electronic publication committed to providing its readers with factual information on select publicly traded companies. SCN is owned and operated by TGR Group, LLC ("TGR"). All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible. Moreover, as detailed below, TGR accepts compensation from third party consultants and/or companies, which it features in the publication and circulation of SCN. To the degrees enumerated herein, SCN should not be regarded as an independent publication.  Click Here or go to http://access.smallcapnetwork.com/compensation_disclosure.html to view our compensation on every company we have ever covered, or visit the following web address: http://access.smallcapnetwork.com/profile_disclosure.html for our full profiles and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts.  TGR Group, LLC has been paid a fee of $30,000 cash and 1,000,000 shares of newly issued restricted stock by Phinder Technologies, Inc. for coverage of the Company.  TGR Group LLC has been paid a fee of $30,000 cash by Titan General for coverage of the company. In addition, TGR Group LLC has been pledged a fee of 100,000 warrants convertible at $1 into restricted shares by Trilogy Capital for coverage of the company.  In October of 2003, TGR Group LLC was paid a fee of $25,000 and one million newly issued restricted shares by Biocurex for coverage of the Company. Under SEC Rule 144, all one million issued restricted shares have been eligible for sale into the public market since October of 2004. In addition, on March 22, 2005, TGR entered into an extended agreement with Biocurex for a fee of 25,000 newly issued restricted shares and on July 1, 2006 TGR entered into another extended agreement with Biocurex for an additional 100,000 shares of newly issued, restricted stock. From time to time TGR sells shares received as compensation for coverage of client companies. Shares received are sold in the open market. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, TGR does not view the sale of the shares as contradictory to any opinions delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.  TGR, its Members and Members' families, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed.  All statements and expressions are the sole opinions of TGR and are subject to change without notice. A profile, description, or other mention of a company within SCN is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.  The profiles, critiques, and other editorial content of SCN may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein.  THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF TGR.  We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.